MoonLake Immunotherapeutics (MLTX)
$10.82+2.27%Close
SELLCRISIS · day 43
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $894M
- Beta
- 1.08
- P/E (TTM)
- -2.84
- Short % float
- 11.25%
- Days to cover
- 4.2
- SI change
- -10.1%
- 1W
- -5.17%
- 1M
- -17.91%
- vs SPY 1W
- -6.33%
- vs SPY 1M
- -20.90%
Industry peers
FMP comparable companies · ranked by market cap
- ORKASELLOruka Therapeutics, Inc.$5.0BCRISISQ -3$82.11+6.25%
- DNTHSELLDianthus Therapeutics, Inc.$4.6BCRISISQ 2$82.37-0.07%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.35+0.63%
- ANABSELLAnaptysBio, Inc.$1.4BCRISISQ 25$45.95-0.56%
- ALMSSELLAlumis Inc.$884MCRISISQ 2$7.16+2.73%
- ATTOSELLAttovia Therapeutics, Inc.$698MQ -44$16.21-0.61%
- ACRSSELLAclaris Therapeutics, Inc.$535MCRISISQ 9$3.83+1.06%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on MLTX?
- LOPJLB’s latest quantitative signal on MoonLake Immunotherapeutics (MLTX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is MLTX in?
- MoonLake Immunotherapeutics (MLTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does MoonLake Immunotherapeutics (MLTX) do?
- MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials f…